[1] DESMOND R, TOWNSLEY D M, DUMITRIU B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug[J]. Blood, 2014,123(12):1818-1825.
[2] FATTIZZO B, LEVATI G, CASSIN R, et al. Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation[J]. Drugs, 2019,79(12):1305-1319.
[3] BRAUNSTEIN I, WANAT K A, ELENITSAS R, et al. Eltrombopag-associated hyperpigmentation[J]. JAMA Dermatol, 2013,149(9):1112-1115.
[4] GILL H, LEUNG G M K, LOPES D, et al. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia[J]. Br J Haematol, 2017,176(6):991-994.
[5] GIBIANSKY E, ZHANG J, WILLIAMS D, et al. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura[J]. J Clin Pharmacol, 2011,51(6):842-856.
[6] ADAMS D F, SELLERS T S. Eltrombopag: investigation of previously reported serum discoloration and negative interference on a total bilirubin diazo method[J]. Arch Pathol Lab Med, 2016,140(5):391-392.
[7] 杨洁茹,王化泉,邵宗鸿. 艾曲泊帕治疗再生障碍性贫血作用机制的研究进展[J]. 中华医学杂志, 2020,100(32):2557-2560.
[8] WINKLER T, FAN X, COOPER J, et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag[J]. Blood, 2019,133(24):2575-2585. |
